Talphera Inc. (TLPH)
0.52
0.02 (4.00%)
At close: Apr 14, 2025, 3:56 PM
0.52
0.64%
After-hours: Apr 14, 2025, 07:50 PM EDT
4.00% (1D)
| Bid | 0.45 |
| Market Cap | 8.9M |
| Revenue (ttm) | 6.68M |
| Net Income (ttm) | -13M |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -1.04 |
| Forward PE | -1.04 |
| Analyst | Buy |
| Ask | 0.55 |
| Volume | 48,166 |
| Avg. Volume (20D) | 61,267 |
| Open | 0.50 |
| Previous Close | 0.50 |
| Day's Range | 0.49 - 0.53 |
| 52-Week Range | 0.45 - 1.27 |
| Beta | 0.19 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditi...
Sector Healthcare
IPO Date Feb 11, 2011
Employees 13
Stock Exchange NASDAQ
Ticker Symbol TLPH
Website https://talphera.com
Analyst Forecast
According to 2 analyst ratings, the average rating for TLPH stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 764.55% from the latest price.
Stock Forecasts1 week ago
-15.53%
Talphera shares are trading higher after the compa...
Unlock content with
Pro Subscription
5 months ago
-25.61%
Talphera shares are trading lower. The company reported Q3 financial results.
